Anakinra

Anakinra
Clinical data

Trade names	Kineret
AHFS/Drugs.com	Monograph
MedlinePlus	a602001
License data	US DailyMed: Anakinra
Pregnancy category	AU: B1
Routes of administration	Subcutaneous
ATC code	L04AC03 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) CA: ℞-only UK: POM (Prescription only) US: ℞-only EU: Rx-only
Pharmacokinetic data
Bioavailability	95%
Metabolism	predominantly kidney
Elimination half-life	4-6 hrs
Identifiers
IUPAC name Recombinant human Interleukin-1 receptor antagonist protein; syn. N2-l-methionyl-interleukin 1 receptor antagonist (human isoform x reduced)
CAS Number	143090-92-0^Y
DrugBank	DB00026^Y
ChemSpider	none
UNII	9013DUQ28K
KEGG	D02934^Y
ChEMBL	ChEMBL1201570^N
Chemical and physical data
Formula	C₇₅₉H₁₁₈₆N₂₀₈O₂₃₂S₁₀
Molar mass	17257.66 g·mol⁻¹
^NY (what is this?) (verify)

Anakinra, sold under the brand name Kineret, is a biopharmaceutical medication used to treat rheumatoid arthritis, cryopyrin-associated periodic syndromes, familial Mediterranean fever, and Still's disease. It is a slightly modified recombinant version of the human interleukin 1 receptor antagonist protein. It is marketed by Swedish Orphan Biovitrum. Anakinra is administered by subcutaneous injection.